Literature DB >> 1418218

Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases.

S Hoyer1.   

Abstract

Reduction of the cerebral metabolic rate of glucose is one of the most predominant abnormalities generally found in the Alzheimer brain, whereas the cerebral metabolic rate of oxygen is only slightly diminished or not at all the beginning of this dementive disorder. This metabolic abnormality may induce severe functional disturbances, obviously preceding morphobiological changes. From the cerebral metabolic rates of oxidized glucose and oxygen, the cerebral ATP formation rate was calculated in incipient early-onset, incipient late-onset and stable advanced dementia of Alzheimer type. A reduction of ATP formation was found from at least 7% in incipient early-onset, to around 20% in incipient late-onset DAT, and from 35% to more than 50% in stable advanced dementia. This approximation was adjusted to findings demonstrating diminished activities of enzymes active in glucose metabolism and formation of oxidation equivalents for ATP production from substrates other than glucose. A reduction for energy formation to the same range was found, as was also recently reported, in vivo in Alzheimer patients. From this rather theoretical point of view, a permanent loss of energy by at least 7-20% in incipient and progressively advancing dementia of the Alzheimer type may be assumed, with an increasing tendency in stable advanced dementia to around 50% energy loss. This energy deficit may have drastic impacts on brain function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418218     DOI: 10.1007/bf03159971

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  32 in total

1.  Genetic and nongenetic variation revealed for the principal components of human gene expression.

Authors:  Anita Goldinger; Anjali K Henders; Allan F McRae; Nicholas G Martin; Greg Gibson; Grant W Montgomery; Peter M Visscher; Joseph E Powell
Journal:  Genetics       Date:  2013-09-11       Impact factor: 4.562

Review 2.  Alzheimer disease--no target for statin treatment. A mini review.

Authors:  Siegfried Hoyer; Peter Riederer
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

Review 3.  From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain.

Authors:  P Riederer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

Review 4.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

5.  Neural membrane phospholipids in Alzheimer disease.

Authors:  K Wells; A A Farooqui; L Liss; L A Horrocks
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

Review 6.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

7.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ.

Authors:  H Lassmann; C Bancher; H Breitschopf; J Wegiel; M Bobinski; K Jellinger; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: comparison to intracerebroventricular streptozotocin.

Authors:  Siegfried Hoyer; Heinrich Lannert
Journal:  J Neural Transm (Vienna)       Date:  2008-08-05       Impact factor: 3.575

9.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 10.  Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.

Authors:  D Allan Butterfield; Tanea Reed; Shelley F Newman; Rukhsana Sultana
Journal:  Free Radic Biol Med       Date:  2007-06-13       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.